Wedbush Upgrades Karyopharm Therapeutics (KPTI) to Outperform
- Wall Street falls as Amazon earnings disappoint
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- 'I'm CEO.' New Book Outlines Merger Conversations Between Elon Musk and Tim Cook
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Wedbush analyst David Nierengarten upgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Neutral to Outperform with a price target of $19.00.
Shares of Karyopharm Therapeutics closed at $11.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: KeyBanc Upgrades Gibraltar Industries (ROCK) to Overweight on Successful Diversification and Valuation
- Argus Upgrades Chubb Corporation (CB) to Buy
- T-Mobile (TMUS) Beats Q2 Estimates as It Continues to Gain Market Share, Analyst Upgrades To 'Outperform' on Compelling Growth Outlook
Create E-mail Alert Related CategoriesUpgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!